Endoscopic Vacuum Therapy for the Treatment of Upper Gastrointestinal Transmural Defects

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1203
Author(s):  
Rui Morais ◽  
Eduardo Rodrigues-Pinto ◽  
Rodrigo Liberal ◽  
Rui Gaspar ◽  
Cristina Fernandes ◽  
...  
2021 ◽  
pp. 5-16
Author(s):  
Vladimir Alekseevich Porkhanov ◽  
Stanislav Nikolayevich Pyatakov ◽  
Alexander Gennadievich Baryshev ◽  
Denis Mikhailovich Melnik ◽  
Maxim Sergeevich Shevchenko ◽  
...  

This article describes the clinical case of treatment of a patient with perforation of the esophageal wall and mediastinitis by the method of endoscopic vacuum therapy. Endoscopic Vacuum Therapy, also known as Negative Pressure Endoscopic Therapy (E-NPWT, EVT), is an innovative endoscopic option for the treatment of transmural defects in hollow organs, as well as a safe and effective instrument that promotes defect healing through macrodeformation, microdeformation, perfusion changes, controls exudate and bacterial clearance. The goal of endoscopic vacuum therapy is to avoid radical surgical interventions and their complications, as well as to improve patient’s quality of life in the postoperative period.


2021 ◽  
Author(s):  
Da Hyun Jung ◽  
Hae-Ryong Yun ◽  
Se Joon Lee ◽  
Na Won Kim ◽  
Cheal Wung Huh

Abstract A transmural defect of the upper gastrointestinal (UGI) tract is a life-threatening condition associated with high morbidity and mortality. Recently, endoscopic vacuum therapy (EVT) has shown rather excellent efficacy in managing UGI defects. We conducted a systematic review and meta-analysis to synthesise the available evidence on the efficacy of EVT in patients with transmural defects of the UGI tract. We searched the PubMed, Cochrane Library, and Embase databases for publications on the effect of EVT on successful closure, mortality, complications, and post-EVT stricture. Methodological quality was assessed using the Newcastle-Ottawa quality assessment scale. This meta-analysis included 29 studies involving 498 participants. The pooled estimate rate of EVT for successful closure was 0.85 (95% confidence interval [CI]: 0.81–0.88). The pooled estimate rate for mortality, complications, and post-EVT stricture was 0.11, 0.10, and 0.14, respectively. According to the aetiology of the transmural defect (perforation vs. leak and fistula), no significant difference was found in successful closure (odds ratio [OR]: 1.45, 95% CI: 0.45–4.67), mortality (OR: 0.77, 95% CI: 0.24–2.46), complications (OR: 0.94, 95% CI: 0.17–5.15), and post-EVT stricture (OR: 0.70, 95% CI: 0.12–4.24). The successful closure rate was significantly higher with EVT than with self-expanding metal stent (SEMS) placement (OR: 3.52, 95% CI: 1.79–6.91). In conclusion, EVT is an effective and safe treatment for treating leaks and fistulae as well as perforations in UGI defects. Moreover, EVT seems to be a better treatment option than SEMS placement in healing UGI defects.


Endoscopy ◽  
2019 ◽  
Vol 52 (05) ◽  
pp. E166-E167 ◽  
Author(s):  
Seung-Hun Chon ◽  
Isabel Bartella ◽  
Martin Bürger ◽  
Isabel Rieck ◽  
Tobias Goeser ◽  
...  

2017 ◽  
Vol 31 (9) ◽  
pp. 3449-3458 ◽  
Author(s):  
Florian Kuehn ◽  
Gunnar Loske ◽  
Leif Schiffmann ◽  
Michael Gock ◽  
Ernst Klar

2014 ◽  
Vol 219 (4) ◽  
pp. e98 ◽  
Author(s):  
Mike G. Laukoetter ◽  
Norbert Senninger ◽  
Mario Colombo-Benkmann ◽  
Rudolf Mennigen

2016 ◽  
Vol 31 (6) ◽  
pp. 2687-2696 ◽  
Author(s):  
Mike G. Laukoetter ◽  
Rudolf Mennigen ◽  
Philipp A. Neumann ◽  
Sameer Dhayat ◽  
Gabriele Horst ◽  
...  

2020 ◽  
pp. 1-7
Author(s):  
Seung-Hun Chon ◽  
Ulrich Töx ◽  
Florian Lorenz ◽  
Isabel Rieck ◽  
Britta Janina Wagner ◽  
...  

<b><i>Introduction:</i></b> Self-expanding metal stents (SEMS) are an established option for treating leaks in the upper gastrointestinal tract, and endoscopic vacuum therapy (EVT) has become a promising alternative. A novel approach is the use of an esophageal hybrid SEMS (VACStent®), which can maintain esophageal passage during EVT. We present the first study demonstrating successful use of the VACStent® for treating leaks of the upper gastrointestinal tract. <b><i>Method:</i></b> We performed a retrospective, single-center study of all patients who underwent endoscopic stenting with the VACStent® of leaks in the upper gastrointestinal tract. <b><i>Results:</i></b> Indications for treatment with the VACStent® were: iatrogenic esophageal perforation (<i>n</i> = 1), spontaneous perforation (<i>n</i> = 2), esophageal fistula (<i>n</i> = 2), and anastomotic leak after upper gastrointestinal surgery (<i>n</i> = 5). Successful application of the VACStent® was achieved in all patients (<i>n</i> = 10; 100%) with a total of 15 interventions. VACStent® therapy was used as a first-line treatment in 5 patient (success rate 80%; 4 out 5 patients) and as a second-line treatment after failed previous endoscopic therapy in 5 patients (success rate 60%; 3 out of 5 patients). Overall, VACStent® treatment was successful in 70% of the patients (7 out of 10). No severe VACStent® treatment-related adverse events occurred. <b><i>Conclusion:</i></b> The initial experience has been that the technical application of the VACStent® is safe and technically feasible. However, due to the small number of patients this study could not show the clear advantages of this novel hybrid stent. More studies are necessary to show significant advantages.


Sign in / Sign up

Export Citation Format

Share Document